Effect and Mechanism of Propranolol on Proliferation, Migration, and Angiogenesis of Human Melanoma A375 cells

doi:10.13701/j.cnki.kqyxyj.2018.02.008

Abstract

Abstract: Objective: To investigate the effects and its mechanism of different dose of propranolol on the proliferation, migration, and angiogenesis of human melanoma A375 cells. Methods: A375 cells were treated with 1, 5, 10 and 20 μmol/L propranolol respectively in vitro. MTT method was used to detect the effects of propranolol on the proliferation ability of A375 cells. Wound healing assay was used to detect the effect of propranolol on the cell migration. Tube formation assay was used to investigate the angiogenesis ability of A375 cells on the HUVEC. RT-PCR and western bolt were used to assay the effect of propranolol on the expression of VEGF, MMP-9, and CXCR4. Results: Propranolol did not significant affect the proliferation of A375 cells. It might suppress the migration, tube formation, and pro-angiogenesis ability of A375 cells by inhibiting the expression of VEGF, MMP-9, and CXCR4 in a dose dependent manner. Conclusion: Propranolol may play a role in suppressing the migration and angiogenesis of A375 cells by inhibiting the expression of VEGF, MMP-9, and CXCR4.

Key words: Propranolol, Melanoma, VEGF, MMP-9, CXCR4

CLC Number:

R739.8

ZOU Hai-xiao, YANG Hai-li, ZHAO Yi-fang, SONG Li. Effect and Mechanism of Propranolol on Proliferation, Migration, and Angiogenesis of Human Melanoma A375 cells[J]. Journal of Oral Science Research, 2018, 34(2): 139-143.

References

[1] Roh MR, Eliades P, Gupta S, et al. Cutaneous melanoma in women [J]. Int J Womens Dermatol, 2017,16(3)∶S11-S15
[2] Coelho M, Soares-Silva C, Brandao D, et al.beta-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives [J]. J Cancer Res Clin Oncol, 2017, 143(2)∶275-291
[3] Wrobel LJ, Le Gal FA. Inhibition of human melanoma growth by a non-cardioselective beta-blocker [J]. J Invest Dermatol,2015, 135(2)∶525-531
[4] Dal Monte M, Casini G, Filippi L, et al.Functional involvement of beta3-adrenergic receptors in melanoma growth and vascularization [J].J Mol Med, 2013,91(12)∶1407-1419
[5] Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro [J]. Nature protocols, 2007,2(2)∶329-333
[6] 韩永付, 韩新光. 27例口腔颌面部恶性黑色素瘤临床分析[J].口腔医学研究,2014(6)∶537-539
[7] Weberpals J, Jansen L, Carr Pr, et al. Beta blockers and cancer prognosis - The role of immortal time bias: A systematic review and meta-analysis [J] . Cancer Treat Rev, 2016, 47∶1-11
[8] Childers Wk, Hollenbeak Cs, Cheriyath P. beta-Blockers Reduce Breast Cancer Recurrence and Breast Cancer Death: A Meta-Analysis [J]. Clinical breast cancer,2015;15(6)∶426-431
[9] Chen Y Z, Bai N, Bi J H, et al. Propranolol inhibits the proliferation, migration and tube formation of hemangioma cells through HIF-1α dependent mechanisms[J]. Braz J Med Biol Res, 2017,50(12)∶e6138
[10] De Giorgi V, Grazzini M, Gandini S, et al. Treatment with beta-blockers and reduced disease progression in patients with thick melanoma[J].Arch Intern Med, 2011,171(8)∶779-781
[11] Lemeshow S, Sorensen Ht, Phillips G, et al. beta-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study [J].Cancer Epidemiol Biomarkers Prev, 2011,20(10)∶2273-2279
[12] Lemeshow S, Sorensen Ht, Phillips G, et al. Beta-blocker usage after malignant melanoma diagnosis and survival: a populationbased nested case-control study[J]. Cancer Epidemiol Biomarkers Prev, 2011,20(10)∶2273-2279
[13] 王晓妍,张祥成,张薇薇,等.VEGF-A和VEGF-C在皮肤恶性黑色素瘤表达的临床病理意义[J].现代生物医学进展,2013,13(26)∶5082-5086
[14] Tang J, Li Z, Lu L, et al. beta-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy[J]Semin Cancer Biol,2013,23(6)∶533-542
[15] Miao C, Liang C, Zhu J, et al. Prognostic role of matrix metalloproteinases in bladder carcinoma: a systematic review and meta-analysis [J]. Oncotarget ,2017, 8(19)∶32309-32321
[16] 宋宁静,王晓楠,陈佳,等.MMP-2和MMP-9在皮肤恶性黑色素瘤中的表达及意义[J].中华全科医学,2011,09(8)∶1174-1174
[17] Kryza D, Debordeaux F, Azema L, et al. Ex Vivo and In Vivo Imaging and Biodistribution of Aptamers Targeting the Human Matrix MetalloProtease-9 in Melanomas [J]. PLoS One,2016,11(2)∶e0149387
[18] Pozzobon T, Goldoni G, Viola A, et al. CXCR4 signaling in health and disease [J]. Immunol Lett,2016 177∶6-15
[19] Mitchell B, Leone D, Feller K, et al. Protein expression of the chemokine receptor CXCR4 and its ligand CXCL12 inprimary cutaneous melanoma-biomarkers of potential utility [J].Hum Pathol,2014,45(10)∶2094-2100
[20] Bi J, Li P, Li C, et al. The SDF-1/CXCR4 chemokine axis in uveal melanoma cell proliferation and migration [J].Tumor Biol,2016,37(3)∶4175-4182